# A Study of Avacopan in Participants With Normal Renal Function and Participants With End-Stage Renal Disease (ESRD)

> **NCT06468826** · PHASE1 · COMPLETED · sponsor: **Amgen** · enrollment: 13 (actual)

## Conditions studied

- End-Stage Renal Disease (ESRD)

## Interventions

- **DRUG:** Avacopan

## Key facts

- **NCT ID:** NCT06468826
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-06-18
- **Primary completion:** 2024-10-05
- **Final completion:** 2024-10-05
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2026-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06468826

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06468826, "A Study of Avacopan in Participants With Normal Renal Function and Participants With End-Stage Renal Disease (ESRD)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06468826. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*